Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm nal-IRI + oxaliplatin + 5-fluorouracil/levoleucovorin in untreated metastatic pancreatic adenocarcinoma in Japan
jRCT2031230733Phase 2Completed
- Sponsor
- Servier
- Start
- Mar 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome, oxaliplatin, fluorouracil and levoleucovorin in pancreatic adenocarcinoma (PDAC), sponsored by Servier. Primary endpoint: Overall response. Started Mar 2024; status: completed.
02
Drugs
irinotecan liposomeoxaliplatinfluorouracillevoleucovorin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031230733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230733.